Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors

New England Journal of Medicine

Volumn 372, Issue 26, 2015, Pages 2499-2508

  Eckel Passow, Jeanette E ^a   Lachance, Daniel H ^a   Molinaro, Annette M ^b,c   Walsh, Kyle M ^b   Decker, Paul A ^a   Sicotte, Hugues ^a   Pekmezci, Melike ^b   Rice, Terri ^b   Kosel, Matt L ^a   Smirnov, Ivan V ^b   Sarkar, Gobinda ^a   Caron, Alissa A ^a   Kollmeyer, Thomas M ^a   Praska, Corinne E ^a   Chada, Anisha R ^a   Halder, Chandralekha ^a   Hansen, Helen M ^b   McCoy, Lucie S ^b   Bracci, Paige M ^c   Marshall, Roxanne ^b   Zheng, Shichun ^b   Reis, Gerald F ^b   Pico, Alexander R ^d   O'Neill, Brian P ^a   Buckner, Jan C ^a   Giannini, Caterina ^a   Huse, Jason T ^e   Perry, Arie ^b   Tihan, Tarik ^b   Berger, Mitchell S ^b   Chang, Susan M ^b   Prados, Michael D ^b   Wiemels, Joseph ^c   Wiencke, John K ^b,c   Wrensch, Margaret R ^b,c   Jenkins, Robert B ^a   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GLADSTONE INSTITUTES   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; TELOMERASE REVERSE TRANSCRIPTASE; DNA; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE 2, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GERM LINE; GLIOMA; HUMAN; IDH GENE; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MIDDLE AGED; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; TERT GENE; CHROMOSOME 1; CHROMOSOME 19; CLASSIFICATION; DNA MUTATIONAL ANALYSIS; GENETICS; GERMLINE MUTATION; KAPLAN MEIER METHOD; MORTALITY; MUTATION; PROPORTIONAL HAZARDS MODEL;

ADULT; AGE OF ONSET; BIOMARKERS, TUMOR; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TELOMERASE;

EID: 84932649039     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1407279     Document Type: Article

References (31)

1. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
2. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
3. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481-98.
4. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61.
5. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 2013; 31:337-43.
6. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligoden-droglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 2013;31:344-50.
7. Guo C, Pirozzi CJ, Lopez GY, Yan H. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target. Curr Opin Neurol 2011;24:648-52.
8. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013; 110:6021-6.
9. Vinagre J, Pinto V, Celestino R, et al. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch 2014;465:119-33.
10. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009;41: 905-8.
11. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41:899-904.
12. Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet 2011;43:1098-103.
13. Jenkins RB, Wrensch MR, Johnson D, et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 2011;204:13-8.
14. Jenkins RB, Xiao Y, Sicotte H, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 2012;44:1122-5.
15. Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 2014;32:783-90.
16. Guan X, Vengoechea J, Zheng S, et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One 2014;9(3):e91216.
17. Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 2012;18: 2490-501.
18. Bielinski SJ, Chai HS, Pathak J, et al. Mayo Genome Consortia: a genotypephenotype resource for genome-wide association studies with an application to the analysis of circulating bilirubin levels. Mayo Clin Proc 2011;86:606-14.
19. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155:462-77.
20. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-22.
21. Labussière M, Boisselier B, Mokhtari K, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology 2014;83:1200-6.
22. Walsh KM, Codd V, Smirnov IV, et al. Variants near TERT and TERC influencing telomere length are associated with highgrade glioma risk. Nat Genet 2014;46:731-5.
23. Huse JT. Elucidating the oncogenic role of ATRX deficiency in glioma. Neuro Oncol 2014;16:Suppl 3:iii45.
24. Bainbridge MN, Armstrong GN, Gramatges MM, et al. Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst 2014;107:384.
25. Enciso-Mora V, Hosking FJ, Kinnersley B, et al. Deciphering the 8q24.21 association for glioma. Hum Mol Genet 2013;22:2293-302.
26. Di Stefano AL, Enciso-Mora V, Marie Y, et al. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol 2013;15:542-7.
27. Rice T, Zheng S, Decker PA, et al. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro Oncol 2013;15: 535-41.
28. Tseng YY, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature 2014;512:82-6.
29. Kim T, Cui R, Jeon YJ, et al. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. Proc Natl Acad Sci U S A 2014;111:4173-8.
30. Schrijver I. Genetics and molecular pathology. In:2013 Surveys and anatomic pathology education programs. Northfield, IL:American College of Pathologists, 2013:203-9.
31. Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology - Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014;24:429-35.